Company Description
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.
It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.
The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services.
The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security.
The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002.
Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
| Country | United States |
| Founded | 1983 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Dr. James A. Hayward Ph.D., Sc.D. |
Contact Details
Address: 50 Health Sciences Drive Stony Brook, New York 11790 United States | |
| Phone | 631-240-8800 |
| Website | adnas.com |
Stock Details
| Ticker Symbol | APDN |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000744452 |
| CUSIP Number | 03815U300 |
| ISIN Number | US03815U3005 |
| Employer ID | 59-2262718 |
| SIC Code | 8734 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Hayward Ph.D., Sc.D. | Chairman, President and Chief Executive Officer |
| Beth M. Jantzen CPA | Chief Financial Officer |
| Judith Murrah | Chief Operating Officer, Chief Information Officer and Secretary |
| Clay Shorrock Esq., J.D. | Chief Legal Officer and Executive Director of Business Development |
| Sanjay M. Hurry | Executive Director of Investor Relations and Corporate Communications |
| Tony Benson | Managing Director of EMEA |
| Joseph L. Magno | Sales Consultant |
| Warren Pearlson | Sales Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K | Current Report |
| Mar 20, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | 424B3 | Prospectus |
| Mar 18, 2024 | UPLOAD | Filing |
| Mar 15, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 14, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 4, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |